ZEUS System (Zio Watch) vs EchoGo Amyloidosis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
These tools are adjacent in the cardiology AI space but serve distinct purposes. ZEUS System (Zio Watch) is designed for long-term continuous monitoring and detection of cardiac arrhythmias such as AFib using a wearable device. In contrast, EchoGo Amyloidosis is an AI-powered screening tool that analyzes echocardiogram video clips to aid in the early detection of cardiac amyloidosis.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
The ZEUS System (Zio Watch) is designed for long-term continuous cardiac monitoring to detect and characterize Atrial Fibrillation (AFib) and other cardiac arrhythmias. EchoGo Amyloidosis is an AI-powered screening tool that analyzes echocardiogram video clips to aid in the early detection of cardiac amyloidosis (CA).
The ZEUS System utilizes continuous ECG and PPG data collected from its wearable biosensor, the Zio Watch. EchoGo Amyloidosis analyzes echocardiogram video clips to identify suspected cardiac amyloidosis.
The ZEUS System provides data and reports through a cloud-based ZioSuite portal and a provider mobile app, complemented by a MyZio patient app for symptom logging. EchoGo Amyloidosis is a cloud-based SaaS model designed for seamless integration with existing clinical workflows and IT infrastructure, including PACS, DICOM, and HL7.
The ZEUS System generates clinically actionable reports with advanced arrhythmia detection and characterization of AFib burden, with high physician agreement (99%). EchoGo Amyloidosis provides a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis, based on its AI-powered analysis of echocardiographic markers.
For EchoGo Amyloidosis, specific reimbursement is available with NTAP Code ICD-10 XXE2X19 for inpatient analysis (Medicare-covered at $1,000 per analysis) and HCPCS Code C9786 (Clinical APC Code 574) for outpatient analysis (covered by Medicare and select commercial insurers at $285 per analysis). The pricing for the ZEUS System requires contacting the vendor.
The ZEUS System is relevant for Cardiology, Family Medicine, and Internal Medicine. EchoGo Amyloidosis is specifically designed for Cardiology.
The ZEUS System offers long-term continuous monitoring for up to 14 days. EchoGo Amyloidosis performs an analysis of echocardiogram video clips as a screening tool for early detection, which is a single-point analysis rather than continuous monitoring.
More Comparisons
Backers
Who funded each tool's parent company.